Patents
Literature
Hiro is an intelligent assistant for R&D personnel, combined with Patent DNA, to facilitate innovative research.
Hiro

322results about How to "Useful in therapy" patented technology

Production of humanized antibodies in transgenic animals

This invention relates to humanized antibodies and antibody preparations produced from transgenic non-human animals. The non-human animals are genetically engineered to contain one or more humanized immunoglobulin loci which are capable of undergoing gene rearrangement and gene conversion in the transgenic non-human animals to produce diversified humanized immunoglobulins. The present invention further relates to novel sequences, recombination vectors and transgenic vectors useful for making these transgenic animals. The humanized antibodies of the present invention have minimal immunogenicity to humans and are appropriate for use in the therapeutic treatment of human subjects.
Owner:THERAPEUTIC HUMAN POLYCLONALS

Production of humanized antibodies in transgenic animals

This invention relates to humanized antibodies and antibody preparations produced from transgenic non-human animals. The non-human animals are genetically engineered to contain one or more humanized immunoglobulin loci which are capable of undergoing gene rearrangement and gene conversion in the transgenic non-human animals to produce diversified humanized immunoglobulins. The present invention further relates to novel sequences, recombination vectors and transgenic vectors useful for making these transgenic animals. The humanized antibodies of the present invention have minimal immunogenicity to humans and are appropriate for use in the therapeutic treatment of human subjects.
Owner:THERAPEUTIC HUMAN POLYCLONALS

Side population cells originated from human amnion and their uses

Cells which may be differentiated at least into nerve cells, which are useful for therapies of brain metabolic diseases, are disclosed. The cells are side population cell separated from human amniotic mesenchymal cell layer, in which expressions of Oct-4 gene, Sox-2 gene and Rex-1 gene are observed by RT-PCR, and which are vimentin-positive and CK19-positive in immunocytostaining.
Owner:SAKURAGAWA NORIO +1

Composition, apparatus, kit and method and uses thereof

A curable composition for use in wound care comprising, apportioned between at least one Part A and at least one Part B: one or more alkenyl-group containing polymers (i) having at least one alkenyl group or moiety per molecule, one or more SiH-containing polymers (ii) having at least one Si—H unit per molecule; and a catalyst (iii) for curing by addition of alkenyl-containing polymer (i) to SiH-containing polymer (ii), Part A and Part B independently having viscosity at 23° C. in the range 5-300 Pa·s, preferably 10-100 Pa s, at a shearing rate of 10 s−1, and when combined in one Part having cure time at 23° C. in the range from 0.5 min to 25 min, wherein when dispensed into a location about a wound dressing, said wound dressing overlying a wound site and skin thereabout, said dispensing being so as to intimately contact and overlie an edge of said dressing and skin about said edge, the composition cures in contact with said edge and skin at 32° C. to an elastomer exhibiting zero or low tack at a time in the range from 0.5 to less than 30 minutes, apparatus for use with said composition comprising dispensing apparatus or wound dressing, a kit comprising the same, and methods of dispensing and curing the same and of using the same in sealing a wound dressing and in treating a wound site of a human in need thereof.
Owner:SMITH & NEPHEW INC

Tetracyclic compound

ActiveUS20120083488A1Excellent inhibitory activityExcellent stabilityBiocideGroup 4/14 element organic compoundsDiseaseCancer
A compound represented by the general Formula (I) below, or a salt or solvate thereof, which is useful as an ALK inhibitor, and is useful for prophylaxis or treatment of a disease accompanied by abnormality in ALK, for example, cancer, cancer metastasis, depression or cognitive function disorder:(meanings of the symbols that are included in the formula are as given in the specification).
Owner:CHUGAI PHARMA CO LTD

Transport and delivery of glutathione into human cells using gold nanoparticles

A method of using specially designed a nanoparticles to contact and then cross the cell, nuclear and / or mitochondrial membrane of the target cell by generating a multitude of complex nanoparticle structures that resonate or vibrate at a specific frequency. Glutathione and / or other molecules or drugs are attached as molecular layers to the nanoparticle structures and the complex particle structures are delivered to the targeted cells. The glutathione and other molecules or drugs are then released from the nanoparticle structures in the destination target cell by using external radiation.
Owner:POP CALIN VIOREL

Method and apparatus for metal artifact reduction in computed tomography

A method for reducing artifacts in an original computed tomography (CT) image of a subject, the original (CT) image being produced from original sinogram data. The method comprises detecting an artifact creating object in the original CT image; re-projecting the artifact creating object in the original sinogram data to produce modified sinogram data in which missing projection data is absent; interpolating replacement data for the missing projection data; replacing the missing projection data in the original sinogram data with the interpolated replacement data to produce final sinogram data; and reconstructing a final CT image using the final sinogram data to thereby obtain an artifact-reduced CT image.
Owner:UNIV LAVAL

Novel Benzopyran Compounds, Compositions and Uses Thereof

Benzopyran compounds with strong anti-estrogenic activity and essentially no estrogenic activity are provided, which are OP-1038, which is 3-(4-hydroxyphenyl)-4-methyl-2-(4-{2-[(3R)-3-methylpyrrolidin-1-yl]ethoxy}phenyl)-2H-chromen-7-ol, and OP-1074, which is (2S)-3-(4-hydroxyphenyl)-4-methyl-2-(4-{2-[(3R)-3-methylpyrrolidin-1-yl]ethoxy}phenyl)-2H-chromen-7-ol. OP-1074 is a pure anti-estrogen when tested in the agonist mode and a complete anti-estrogen when tested in the antagonist mode. These compounds are useful for the treatment or prevention of a variety of conditions that are modulated through the estrogen receptor in mammals including humans.
Owner:OLEMA PHARMA

Oxazole compound and pharmaceutical composition

The present invention provides a oxazole compound represented by Formula (1), or a salt thereof:wherein R1 is an aryl group which may have one or more substituents; R2 is an aryl group or a nitrogen atom-containing heterocyclic group each of which may have one or more substituents; and W is a divalent group represented by —Y1-A1- or —Y2—C(═O)— wherein Y1 is a group such as —C(═O)—, A1 is a group such as a lower alkylene group, and Y2 is a group such as a piperazinediyl group. The oxazole compound has a specific inhibitory action against phosphodiesterase 4.
Owner:OTSUKA PHARM CO LTD

Novel thyroid hormone receptor ligand, medicinal compositions containing the same and use thereof

The present invention provides a compound represented by general formula (I): or pharmaceutically acceptable salts thereof, wherein W is O, S(O)m, CH2 and the like; R1 is halogen, lower alkyl, halo-lower alkyl, CN and the like; R3 is hydrogen and the like; R4 is hydrogen, halogen, alkyl, halo-lower alkyl, substituted alkyl, aryl, aralkyl, alkoxy, substituted alkoxy, alkanoyl, aroyl, —CONR7(R8), —S(O)mR9, —SO2NR7(R8) and the like; R5 is hydrogen, halogen, alkyl, substituted alkyl and the like; A is —N(R6)CO-A1-COR10 and the like; pharmaceutical compositions containing them and their uses, which have a high affinity to human thyroid hormone receptors, in particular human thyroid hormone receptor β.
Owner:KISSEI PHARMA

Spinal muscular atrophy treatment via targeting smn2 catalytic core

The present invention is directed to methods and compositions for blocking the effect of the intronic inhibitory splicing region of intron 7 of the SMN2 gene. The compositions and methods of the instant invention include short oligonucleotide reagents (e.g., oligoribonucleotides) that effectively target sites in the SMN2 pre-mRNA, thereby modulating the splicing of SMN2 pre-mRNA to include exon 7 in the processed transcript. The short target regions are 8-mers and 5-mers and also include the identification of a single nucleotide base that is essential for initiating a long distance stearic inhibitory interactions as well as novel targets distant from intron 7 which block the intronic inhibitory splicing of the same. These short target regions and concomitant inhibitory blocking oligonucleotides are less expensive and easier to manufacture and are small enough to cross the blood brain barrier.
Owner:IOWA STATE UNIV RES FOUND

Hydrolysable hydrogels for controlled release

InactiveUS7060296B2Poorly controllable release behaviourImprove applicabilityPowder deliverySolution deliveryCross-linkControlled release
The present invention relates to a biodegradable hydrogel comprising bonds which are hydrolyzable under physiological conditions. More particularly, the hydrogel consists of two interpenetrating polymer networks interconnected to one another through hydrolyzable spacers. In addition, the invention relates to a method for the preparation of a hydrogel, wherein macromolecules, e.g., polymers which contain bonds which are hydrolyzable under physiological conditions, are cross-linked in an aqueous solution.
Owner:UTRECHT UNIVERSITY

Systems and methods for frameless image-guided biopsy and therapeutic intervention

A system and a method of performing a frameless image-guided biopsy uses imaging, a six-dimensional robotic couch system, a laser guidance system, an optical distance indicator, and a needle control apparatus. A planning CT scan is made of the patient with stereotactic fiduciary markers to localize and produce digitally reconstructed radiographs. Two stereoscopic images are generated using an imaging device to visualize and identify a target tumor. The images are fused with the digitally reconstructed radiographs of the planning CT scan to process tumor location. The tumor location data are communicated to the movable robotic couch to position the target tumor of the patient at a known isocenter location. A biopsy needle is guided with a laser alignment mechanism towards the isocenter at the determined depth using a needle positioning apparatus and an Optical Distance Indicator, and a biopsy sample of the target tumor is obtained.
Owner:VOXEL RAD

Novel cyclic compound having 4-pyridylalkylthio group having substituted or unsubstituted amino group introduced therein

InactiveUS20070149574A1Useful in therapyExcellent cell proliferation inhibitory effectBiocideSenses disorderDiseaseAryl
A novel cyclic compound having a 4-pyridylalkylthio group having an (un)substituted amino group introduced therein or a salt thereof. They are useful as a medicine. The cyclic compound is a compound represented by the following formula (1), which is useful for the treatment of diseases in which angiogenesis participates. In the following formula (1), ring A represents a benzene ring or a 5- or 6-membered aromatic heterocycle optionally fused with a cycloalkane ring; B represents alkylene; R1 and R2 each represents H, (substituted) aryl, (substituted) heterocyclic group, etc.; R3 and R4 each represents H, (substituted) alkyl, (substituted) cycloalkyl, -Z-R5, etc.; R5 represents (substituted) alkyl, (substituted) aryl, (substituted) heterocyclic group, etc.; X and Y each represents H, etc.; Z represents —CO—, —COO—, —CONR6—, —SO2—, etc.; R6 represents H, etc.; p is 0, 1, or 2; and q is 0 or 1.
Owner:SANTEN PHARMA CO LTD

Recoverable Valve Stent

A recoverable, safe and reliable valve stent for unidirectional flow of human lumen which can be implanted temporarily or for a long term and is used in the interventional therapy so as to obstruct from anisotropic flow, in the case of lung diseases. It comprises a cylindrical stent made up of memory alloy material. In particular, an elastic diaphragm is arranged inside the cylindrical stent and at least one gap is arranged on the diaphragm so that the spring piece is divided into a bendable section. One end of the cylindrical stent is provided with a fixed rear clip which is used to fix the alloy material making up the cylindrical stent. The rear clip is provided with screwthreads which can be connected with the conveyor. The stent in the present invention is in a structure without hook body, so the stent can be accurately positioned, adjusted and placed or recovered in double directions with strong anti-backflow ability.
Owner:BEIJING PUYI MEDICAL TECH CO LTD

Methods for in vitro expansion of hematopoietic stem cells

The invention relates to methods of obtaining compositions for generating multipotent hematopoietic stem progenitor cells comprising expansion of hematopoietic stem cells in the presence of HDACI and IDM. Methods of obtaining compositions enriched in hematopoietic megakaryocyte progenitor cells are also provided. Compositions enriched for stem cells and populations of cells obtained therefrom are also provided by the invention.
Owner:THE BOARD OF TRUSTEES OF THE UNIV OF ILLINOIS

Diagnostic and therapeutic agents

InactiveUS20090180958A1Highly selective and potent targetingPotential riskTetrapeptide ingredientsCyclic peptide ingredientsDiseaseTumor target
The present invention relates to tumor targeting units comprising a peptide sequence X—R—Y—P—Zn, or a pharmaceutically or physiologically acceptable salt thereof. The invention further relates to tumor targeting agents comprising at least one targeting unit according to the present invention, directly or indirectly coupled to at least one effector unit. The present invention further relates to diagnostic or pharmaceutical compositions comprising at least one targeting unit or at least one targeting agent according to the present invention, and to the use of targeting units or targeting agents according to the present invention for the preparation of a medicament for the treatment of cancer or cancer related diseases, especially for the treatment of non-small cell lung cancer or its metastases.
Owner:KARYON CTT

Stabilized A-beta protofibrillar aggregates

Described and claimed herein are methods for producing chemically stabilized Aβ protofibrillar aggregates, and compositions made therefrom. Compositions produced are useful in facilitating detailed studies of Aβ protofibril structure, fibril formation, and progression of Aβ related diseases, e.g., Alzheimers disease. In addition, chemically stabilized protofibrillar structures can be used as tools to generate and / or screen for antibodies specific for protofibrils. Antibodies specific for protofibrils can be used as diagnostic tools or as therapeutics in the diagnosis or treatment of, e.g., Alzheimer's disease. Finally, chemically stabilized protofibrillar structures can be used in the preparation of therapeutic or prophylactic vaccines.
Owner:UNIV OF TENNESSEE RES FOUND

Fused Heterocyclic Compound

InactiveUS20070244132A1Superior tyrosine kinase inhibitory actionLow toxicBiocideOrganic active ingredientsArylHydrogen atom
The present invention relates to a compound represented by the formula: wherein W is C(R1) or N, each A is an optionally substituted aryl group or a heteroaryl group, X1 is —NR3—Y1—, —O—, —S—, —SO—, —SO2— or —CHR3— wherein R3 is a hydrogen atom or an optionally substituted aliphatic hydrocarbon group, or R3 is optionally bonded to A to form an optionally substituted ring structure, R1 is a hydrogen atom or an optionally substituted group bonded via a carbon atom, a nitrogen atom or an oxygen atom, R2 is a hydrogen atom or optionally substituted group bonded via a carbon atom or a sulfur atom, or R1 and R2, or R2 and R3 are optionally bonded to form an optionally substituted ring structure, or a salt thereof, and a tyrosine kinase inhibitor or an agent for the prophylaxis or treatment of cancer, which contains this compound or a prodrug thereof.
Owner:TAKEDA PHARMA CO LTD

Aziridine bisphenol ethers and related compounds and methods for their use

Compounds having a structure of Formula I:or a pharmaceutically acceptable salt, tautomer or stereoisomer thereof, wherein R, R1, R2, R3, R4, M1, M2, X, L1, L2, J1, J2, a1, a2, b1 and b2 are as defined herein, and wherein at least one of M2 or L2 is a moiety comprising an aziridine, acrylamide or sulfonate functional group, are provided. Uses of such compounds for treatment of various indications, including prostate cancer as well as methods of treatment involving such compounds are also provided.
Owner:THE UNIV OF BRITISH COLUMBIA +1

Nitrogenous heterocyclic derivatives and medicine thereof

The present invention provides a novel nitrogen-containing heterocyclic compound useful as a phosphodiesterase-4 inhibitor, and a medicament comprising the same. Further, the present invention provides a nitrogen-containing heterocyclic compound represented by the following formula, its salt or hydrates thereof, and a medicament comprising the same.wherein the ring A is an aromatic hydrocarbon ring which may have a heteroatom, the ring B represents (a) a saturated hydrocarbon ring, (b) an unsaturated hydrocarbon ring, (c) a saturated heterocyclic ring or (d) an unsaturated heterocyclic ring, all of which may have a substituent group.
Owner:EISIA R&D MANAGEMENT CO LTD

Functional therapeutic heater

A breathable electrical heater element for a topical application device such as a wound dressing or a therapeutic heating pad is disclosed. The heater element is formed by photochemically etching a track pattern onto a porous metallised fabric (e.g. nickel coated woven polyester). The heater element has a skin or wound contact layer laminated to the front face of the heater element. An adhesive layer is laminated to the back face of the heater element. The adhesive layer forms an overhang to provide an adhesive border around the wound contact layer to adhere the device to the skin of a patient. Therapeutically active drugs (optionally microencapsulated) may be incorporated into the skin or wound contact layer. Operation of the heater element causes the skin or wound contact layer to release the active drugs to the skin or wound of the patient. Appropriate control of the temperature of the heater element allows control of the release of the active drugs.
Owner:NEL TECH
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products